StockNews.com downgraded shares of IDEXX Laboratories (NASDAQ:IDXX - Free Report) from a buy rating to a hold rating in a report published on Saturday.
Several other research firms have also recently weighed in on IDXX. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Finally, Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $523.75.
View Our Latest Analysis on IDEXX Laboratories
IDEXX Laboratories Trading Down 0.2 %
Shares of NASDAQ IDXX traded down $0.63 during trading on Friday, reaching $404.02. The company had a trading volume of 985,075 shares, compared to its average volume of 619,480. The stock has a market cap of $32.74 billion, a P/E ratio of 37.87, a PEG ratio of 3.41 and a beta of 1.50. The company's fifty day moving average price is $426.75 and its 200-day moving average price is $432.85. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories has a 12 month low of $356.14 and a 12 month high of $548.88.
Insider Activity at IDEXX Laboratories
In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.
Institutional Trading of IDEXX Laboratories
Hedge funds have recently made changes to their positions in the stock. Insight Wealth Strategies LLC raised its position in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock worth $4,174,000 after purchasing an additional 7,041 shares during the period. Sax Wealth Advisors LLC boosted its position in shares of IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after purchasing an additional 617 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after buying an additional 800 shares during the period. Paragon Capital Management Inc. grew its holdings in IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock worth $1,579,000 after purchasing an additional 782 shares during the period. Finally, Manitou Investment Management Ltd. increased its position in IDEXX Laboratories by 491.0% during the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock valued at $21,582,000 after buying an additional 43,369 shares in the last quarter. 87.84% of the stock is owned by institutional investors.
IDEXX Laboratories Company Profile
(
Get Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
